Article
Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes.
Human genetics - 1 Jul 2011
Pajic Marina, Scarlett Christopher J, Chang David K, Sutherland Robert L, Biankin Andrew V
Abstract excerpt
Defining key driver mutations in cancer, the resulting aberrations in molecular mechanisms and the subsequent phenotype underpins the development and implementation of novel personalized medicine strategies. The literature is replete with biomarkers of prognosis and therapeutic responsiveness identified in single cohorts of patients that have not been independently validated and as a consequence, not developed....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.